Australia markets close in 5 hours 57 minutes
  • ALL ORDS

    7,577.20
    +18.40 (+0.24%)
     
  • ASX 200

    7,312.30
    +9.80 (+0.13%)
     
  • AUD/USD

    0.7714
    -0.0001 (-0.01%)
     
  • OIL

    71.16
    +0.28 (+0.40%)
     
  • GOLD

    1,867.80
    +1.90 (+0.10%)
     
  • BTC-AUD

    52,338.32
    +1,716.18 (+3.39%)
     
  • CMC Crypto 200

    1,009.36
    +40.52 (+4.18%)
     
  • AUD/EUR

    0.6363
    +0.0001 (+0.02%)
     
  • AUD/NZD

    1.0792
    -0.0002 (-0.02%)
     
  • NZX 50

    12,582.75
    +20.58 (+0.16%)
     
  • NASDAQ

    14,128.20
    +129.90 (+0.93%)
     
  • FTSE

    7,146.68
    +12.62 (+0.18%)
     
  • Dow Jones

    34,393.75
    -85.85 (-0.25%)
     
  • DAX

    15,673.64
    -19.63 (-0.13%)
     
  • Hang Seng

    28,842.13
    +103.23 (+0.36%)
     
  • NIKKEI 225

    29,161.80
    0.00 (0.00%)
     

Global Sexually Transmitted Diseases (STDs) Drug Market Research Report 2021-2027 - ResearchAndMarkets.com

·3-min read

DUBLIN, Jun 11, 2021--(BUSINESS WIRE)--The "Sexually Transmitted Diseases (STDs) Drug - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Global Sexually Transmitted Diseases (STDs) Drug Market to Reach $91.7 Billion by 2027

Amid the COVID-19 crisis, the global market for Sexually Transmitted Diseases (STDs) Drug estimated at US$47.7 Billion in the year 2020, is projected to reach a revised size of US$91.7 Billion by 2027, growing at a CAGR of 9.8% over the analysis period 2020-2027.

Chlamydia, one of the segments analyzed in the report, is projected to record a 10% CAGR and reach US$14.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Gonorrhea segment is readjusted to a revised 8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $12.9 Billion, While China is Forecast to Grow at 13.1% CAGR

The Sexually Transmitted Diseases (STDs) Drug market in the U.S. is estimated at US$12.9 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$19.3 Billion by the year 2027 trailing a CAGR of 12.9% over the analysis period 2020 to 2027.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.7% and 8.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.7% CAGR.

Syphilis Segment to Record 7.8% CAGR

In the global Syphilis segment, USA, Canada, Japan, China and Europe will drive the 7.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$699.9 Million in the year 2020 will reach a projected size of US$1.1 Billion by the close of the analysis period.

China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$13.2 Billion by the year 2027, while Latin America will expand at a 9.1% CAGR through the analysis period.

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Influencer Market Insights

  • World Market Trajectories

  • Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS (Total 46 Featured):

  • AbbVie, Inc.

  • Bayer Healthcare AG

  • Bristol-Myers Squibb Company

  • Eli Lilly and Company

  • F. Hoffmann-La Roche AG

  • Gilead Sciences, Inc.

  • GlaxoSmithKline PLC

  • Johnson & Johnson

  • Merck & Co., Inc.

  • Pfizer, Inc.

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

  • UNITED STATES

  • CANADA

  • JAPAN

  • CHINA

  • EUROPE

  • FRANCE

  • GERMANY

  • ITALY

  • UNITED KINGDOM

  • SPAIN

  • RUSSIA

  • REST OF EUROPE

  • ASIA-PACIFIC

  • AUSTRALIA

  • INDIA

  • SOUTH KOREA

  • REST OF ASIA-PACIFIC

  • LATIN AMERICA

  • ARGENTINA

  • BRAZIL

  • MEXICO

  • REST OF LATIN AMERICA

  • MIDDLE EAST

  • IRAN

  • ISRAEL

  • SAUDI ARABIA

  • UNITED ARAB EMIRATES

  • REST OF MIDDLE EAST

  • AFRICA

IV. COMPETITION

  • Total Companies Profiled: 46

For more information about this report visit https://www.researchandmarkets.com/r/qn4268

View source version on businesswire.com: https://www.businesswire.com/news/home/20210611005275/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900